May 21st 2024
For decoding biomarkers, a multistage system is just the beginning
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
The Ins and Outs of Lubricating Eye Drops
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)
View More
Community Practice Connections™: Expert Perspectives in Diabetic Macular Edema – Considering Pathogenesis & Inflammation in Treatment Selection
View More
Community Practice Connections™: Novel Treatment Strategies in the Management of nAMD & DME - Lessons from Clinical Trial and Real-World Data
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (CME Credit)
View More
Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME – Optimizing Reduction in Treatment Burden
View More
Medical Crossfire®: Considerations for the Use of Biosimilars in Retinal Disease - Are You Prepared for a New Paradigm? (COPE Credit)
View More
EyeCon 2024
September 27-28, 2024
Register Now!
Heading to AAO? You’re invited to a CME dinner. Or join virtually!
Date TBA
Register Now!
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
Aflibercept boosts BCVA in DME
October 31st 2014Patients with diabetic macular oedema (DME) who received aflibercept injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to those who received either bevacizumab or ranibizumab.
Ranibizumab long-term observational data presented
September 19th 2014Long-term observational data presented at the 2014 European Society of Retina Specialists (EURETINA) conference support the safety and efficacy profile of the anti-vascular endothelial growth factor (anti-VEGF) agent ranibizumab (Lucentis, Novartis) for the treatment of appropriate patients across its indications
Dexamethasone implant authorized for DME
September 17th 2014The European Commission has extended marketing authorization for an intravitreal implant with 700 mcg of dexamethasone in an applicator (Ozurdex, Allergan) for the treatment of adults with visual impairment caused by diabetic macular oedema (DME) who have pseudophakia or whose condition is considered insufficiently responsive to or unsuitable for non-corticosteroid therapy.
Age-related HS changes have implications for AMD
August 22nd 2014Researchers examining age-related changes in heparan sulphate (HS) quantity and composition in human Bruch's membrane (BrM) have discovered that the quantity greatly decreases with age, resulting in fewer binding sites for complement factor H (CFH) and affecting the ability of the 402H variant of CFH to bind BrM.
Aflibercept effective but concerns raised over long-term use
August 15th 2014Aflibercept is effective in inhibiting vascular endothelial growth factor (VEGF) for a prolonged period of time, but possible side effects draw concerns about its long-term use in patients with age-related macular degeneration, diabetic macular oedema and retinal vein occlusion, according to the conclusions of a new study.
Inhibiting thrombin activity could treat PVR
August 8th 2014Inhibiting thrombin activity may be a treatment option for proliferative vitreoretinopathy (PVR), given that such activity is increased in the vitreous of patients with the disease and is associated with the activation of pro-inflammatory and pro-fibrotic pathways in retinal pigment epithelium (RPE) cells.
Anti-VEGFs clear bloodstream at different rates
July 17th 2014The systemic pharmacokinetics and pharmacodynamics of three anti-vascular endothelial growth factor (VEGF) treatments after they are administered intravitreally differ in ways that "may provide biological plausibility for potential differences in systemic safety risk," according to recently published research.
Macular disease accounts for nearly 10% of world's blindness
July 11th 2014In 2010, 2.1 million people were blind and 6 million people were visually impaired because of macular diseases other than diabetic maculopathy, according to a meta-analysis conducted by members of the Vision Loss Expert Group of the Global Burden of Disease Study Group.
Ocular nutrition: What physicians should be telling their patients
July 1st 2014The AREDS 1 and 2 studies provide important information about the role of ocular nutrition in macular degeneration. However, to benefit patients, the findings must be condensed into clear and concise advice that will help them select appropriate vitamin supplements and follow a healthy lifestyle.
Combined treatment for BRVO reduces re-injection need
June 5th 2014Patients who have macular oedema secondary to branch retinal vein occlusion (BRVO) see improved anatomic and functional outcomes with combined intravitreal bevacizumab (IVB) and intravitreal triamcinolone acetate (IVT) therapy when it is delivered early in the disease process, according to the findings of recently published research.